Connected device company Cohero Health has closed a $9M Series A financing round to fund development of its BreatheSmart platform, business development, and clinical trials, the company said.
One of the company’s new investors is Heitkamp & Thumann Group, parent company of H&T Presspart, which is partnered with Cohero Health on an eMDI. Other Investors include Three Leaf Ventures, BioAdvance, and Zaffre investments (Blue Cross Blue Shield of Massachusetts), GIS Strategic Ventures, and PS Health Ventures.
According to the company, the BreatheSmart platform, which monitors inhaler use and lung function, has been shown to increase adherence rates by 250% over standard of care.
Cohero Health Co-Founder and CEO Melissa Manice said, “We started Cohero Health with the goal of empowering pulmonary patients to engage in their care. This investment will sustain this mission, transforming respiratory care for patients and the many stakeholders that support the respiratory community.”
Co-Founder and COO Dan Weinstein added, “With this investment, we will further progress our leading connected health platform, and scale our business to meet market demand. We’re proud of what we have achieved so far, and excited to continue setting the new standard for respiratory care.”
Read the Cohero Health press release.
